Autor: "Drucker DJ" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans.
Autorzy :: Baggio LL; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada.
Varin EM; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada.
Koehler JA; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada.
Cao X; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada.
Lokhnygina Y; Duke Clinical Research Institute, Duke University, Durham, NC, USA.
Stevens SR; Duke Clinical Research Institute, Duke University, Durham, NC, USA.
Holman RR; Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Drucker DJ; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada. drucker@lunenfeld.ca.; Pokaż więcej
Źródło :: Nature communications [Nat Commun] 2020 Jul 28; Vol. 11 (1), pp. 3766. Date of Electronic Publication: 2020 Jul 28.
Typ publikacji :: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Cardiovascular Diseases/*immunology
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl Peptidase 4/*blood
Dipeptidyl-Peptidase IV Inhibitors/*adverse effects
Inflammation/*immunology
Aged ; Animals ; Biomarkers/analysis ; Biomarkers/metabolism ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/immunology ; Diet, Atherogenic/adverse effects ; Diet, High-Fat/adverse effects ; Dipeptidyl Peptidase 4/immunology ; Dipeptidyl Peptidase 4/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/administration & dosage ; Disease Models, Animal ; Female ; Glucagon-Like Peptide-1 Receptor/genetics ; Humans ; Inflammation/blood ; Inflammation/diagnosis ; Inflammation/drug therapy ; Inflammation Mediators/analysis ; Inflammation Mediators/metabolism ; Male ; Metformin/administration & dosage ; Mice ; Mice, Knockout ; Middle Aged ; Protein Isoforms/antagonists & inhibitors ; Protein Isoforms/blood ; Protein Isoforms/metabolism ; Sitagliptin Phosphate/administration & dosage ; Sitagliptin Phosphate/adverse effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications.
Autorzy :: Drucker DJ; From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario, Canada.; Pokaż więcej
Źródło :: Endocrine reviews [Endocr Rev] 2020 Jun 01; Vol. 41 (3).
Typ publikacji :: Journal Article; Review
MeSH Terms :: Betacoronavirus*
Coronavirus Infections/*complications
Diabetes Mellitus, Type 2/*complications
Diabetes Mellitus, Type 2/*drug therapy
Pneumonia, Viral/*complications
Angiotensin-Converting Enzyme 2 ; Animals ; COVID-19 ; Coronavirus Infections/metabolism ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Dipeptidyl Peptidase 4/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Gastrointestinal Tract/metabolism ; Humans ; Insulin/therapeutic use ; Lung/metabolism ; Obesity/complications ; Obesity/metabolism ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/metabolism ; Receptors, Coronavirus ; Receptors, Virus/metabolism ; Risk Factors ; SARS-CoV-2 ; Serine Endopeptidases/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Treatment of type 2 diabetes with the designer cytokine IC7Fc.
Autorzy :: Findeisen M; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Allen TL; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Henstridge DC; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Kammoun H; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Brandon AE; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
Baggio LL; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Watt KI; Centre of Muscle Research, Department of Physiology, The University of Melbourne, Melbourne, Victoria, Australia.
Pal M; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.
Cron L; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Estevez E; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Yang C; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Kowalski GM; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.; Institute for Physical Activity and Nutrition, Deakin University, Melbourne, Victoria, Australia.
O'Reilly L; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Egan C; Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.
Sun E; Molecular & Cellular Physiology Laboratory, Flinders University, Adelaide, South Australia, Australia.
Thai LM; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Krippner G; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Adams TE; CSIRO Manufacturing, Melbourne, Victoria, Australia.
Lee RS; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Grötzinger J; Department of Biochemistry, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.
Garbers C; Institut Für Pathologie, Otto von Guericke University, Magdeburg, Germany.
Risis S; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Kraakman MJ; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Mellet NA; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Sligar J; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Kimber ET; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Young RL; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
Cowley MA; Department of Physiology, Monash University, Melbourne, Victoria, Australia.
Bruce CR; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.; Institute for Physical Activity and Nutrition, Deakin University, Melbourne, Victoria, Australia.
Meikle PJ; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia.
Baldock PA; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Gregorevic P; Centre of Muscle Research, Department of Physiology, The University of Melbourne, Melbourne, Victoria, Australia.
Biden TJ; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
Cooney GJ; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
Keating DJ; Molecular & Cellular Physiology Laboratory, Flinders University, Adelaide, South Australia, Australia.
Drucker DJ; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Rose-John S; Department of Biochemistry, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.
Febbraio MA; The Garvan Institute of Medical Research, Sydney, New South Wales, Australia. .; Baker Heart & Diabetes Institute, Melbourne, Victoria, Australia. .; Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia. .; Pokaż więcej
Źródło :: Nature [Nature] 2019 Oct; Vol. 574 (7776), pp. 63-68. Date of Electronic Publication: 2019 Sep 25.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Cytokine Receptor gp130/*metabolism
Cytokines/*chemical synthesis
Cytokines/*therapeutic use
Diabetes Mellitus, Type 2/*drug therapy
Adaptor Proteins, Signal Transducing/metabolism ; Animals ; Binding, Competitive ; Cytokines/chemistry ; Diabetes Mellitus, Type 2/metabolism ; Drug Design ; Fatty Liver/prevention & control ; Glucose Tolerance Test ; Humans ; Hyperglycemia/drug therapy ; Hyperglycemia/metabolism ; Incretins/metabolism ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/metabolism ; Male ; Mice ; Muscle, Skeletal/drug effects ; Obesity/metabolism ; Pancreas/metabolism ; Phosphoproteins/metabolism ; Protein Engineering ; Receptors, Interleukin-6/metabolism ; Signal Transduction ; Transcription Factors ; Weight Gain/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Precision medicine in the management of type 2 diabetes.
Autorzy :: Gloyn AL; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
Drucker DJ; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada. Electronic address: drucker@lunenfeld.ca.; Pokaż więcej
Źródło :: The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2018 Nov; Vol. 6 (11), pp. 891-900. Date of Electronic Publication: 2018 Apr 23.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Precision Medicine*
Diabetes Mellitus, Type 2/*diagnosis
Diabetes Mellitus, Type 2/*therapy
Hypoglycemic Agents/*therapeutic use
Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/genetics ; Genetic Predisposition to Disease ; Humans ; Pharmacogenetics ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications.
Autorzy :: Drucker DJ; Department of Medicine, Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, Ontario, Canada drucker@lunenfeld.ca.; Pokaż więcej
Źródło :: Diabetes [Diabetes] 2018 Sep; Vol. 67 (9), pp. 1710-1719.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Diabetes Complications/*prevention & control
Diabetes Mellitus, Type 1/*drug therapy
Diabetes Mellitus, Type 2/*drug therapy
Glucagon-Like Peptide-1 Receptor/*agonists
Hypoglycemic Agents/*therapeutic use
Animals ; Biomedical Research/methods ; Biomedical Research/trends ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/metabolism ; Diabetes Mellitus, Type 1/pathology ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/metabolism ; Diabetes Mellitus, Type 2/pathology ; Drug Approval ; Gene Expression Regulation/drug effects ; Glucagon-Like Peptide-1 Receptor/genetics ; Glucagon-Like Peptide-1 Receptor/metabolism ; Humans ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/pharmacology ; Islets of Langerhans/drug effects ; Islets of Langerhans/metabolism ; Islets of Langerhans/pathology ; Kidney/drug effects ; Kidney/metabolism ; Kidney/pathology ; Organ Specificity
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Autorzy :: Drucker DJ; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, 600 University Avenue, Mailbox 39, Toronto, ON M5G 1X5, Canada. Electronic address: drucker@lunenfeld.ca.; Pokaż więcej
Źródło :: Cell metabolism [Cell Metab] 2018 Apr 03; Vol. 27 (4), pp. 740-756.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Diabetes Mellitus, Type 1/*therapy
Diabetes Mellitus, Type 2/*therapy
Glucagon-Like Peptide 1/*pharmacology
Obesity/*therapy
Animals ; Blood Glucose/drug effects ; Eating/drug effects ; Glucagon-Like Peptide 1/adverse effects ; Glucagon-Like Peptide 1/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptide-1 Receptor/physiology ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin/metabolism ; Mice ; Rats ; Weight Gain/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α in Patients With Type 2 Diabetes.
Autorzy :: Lovshin JA; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada .; Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Rajasekeran H; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Lytvyn Y; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Lovblom LE; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Khan S; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Alemu R; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Locke A; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Lai V; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
He H; Pharmacokinetic Pharmacodynamics and Drug Metabolism, Merck and Co., Inc., Rahway, NJ.
Hittle L; Pharmacokinetic Pharmacodynamics and Drug Metabolism, Merck and Co., Inc., Rahway, NJ.
Wang W; Pharmacokinetic Pharmacodynamics and Drug Metabolism, Merck and Co., Inc., Rahway, NJ.
Drucker DJ; Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Cherney DZI; Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.; Department of Physiology, University of Toronto, Toronto, Ontario, Canada.; Pokaż więcej
Źródło :: Diabetes care [Diabetes Care] 2017 Aug; Vol. 40 (8), pp. 1073-1081. Date of Electronic Publication: 2017 May 26.
Typ publikacji :: Journal Article; Randomized Controlled Trial
MeSH Terms :: Chemokine CXCL12/*blood
Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*adverse effects
Hypoglycemic Agents/*adverse effects
Natriuresis/*drug effects
Aged ; Blood Pressure/drug effects ; Diabetes Mellitus, Type 2/blood ; Dipeptidyl-Peptidase IV Inhibitors/administration & dosage ; Double-Blind Method ; Female ; Hemodynamics ; Humans ; Hypoglycemic Agents/administration & dosage ; Kidney/drug effects ; Kidney/metabolism ; Male ; Middle Aged ; Prospective Studies ; Sitagliptin Phosphate/administration & dosage ; Sitagliptin Phosphate/adverse effects ; Sodium-Glucose Transporter 2/blood ; Sodium-Glucose Transporter 2 Inhibitors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: TCF1 links GIPR signaling to the control of beta cell function and survival.
Autorzy :: Campbell JE; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Ussher JR; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Mulvihill EE; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Kolic J; Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.; Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
Baggio LL; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Cao X; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Liu Y; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Lamont BJ; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Morii T; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
Streutker CJ; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Tamarina N; Department of Medicine, Kovler Diabetes Center, University of Chicago, Chicago, USA.
Philipson LH; Department of Medicine, Kovler Diabetes Center, University of Chicago, Chicago, USA.
Wrana JL; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.
MacDonald PE; Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada.; Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
Drucker DJ; Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Pokaż więcej
Źródło :: Nature medicine [Nat Med] 2016 Jan; Vol. 22 (1), pp. 84-90. Date of Electronic Publication: 2015 Dec 07.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Diabetes Mellitus, Experimental/*genetics
Diabetes Mellitus, Type 2/*genetics
Hepatocyte Nuclear Factor 1-alpha/*genetics
Insulin/*metabolism
Insulin-Secreting Cells/*metabolism
RNA, Messenger/*metabolism
Receptors, Gastrointestinal Hormone/*genetics
T Cell Transcription Factor 1/*genetics
Animals ; Apoptosis/genetics ; Blotting, Western ; Diabetes Mellitus, Experimental/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Gene Knockout Techniques ; Glucose Tolerance Test ; Hepatocyte Nuclear Factor 1-alpha/metabolism ; Humans ; Insulin Resistance/genetics ; Insulin Secretion ; Islets of Langerhans/metabolism ; Male ; Mice ; Real-Time Polymerase Chain Reaction ; Receptors, Gastrointestinal Hormone/metabolism ; Sequence Analysis, RNA ; Signal Transduction ; T Cell Transcription Factor 1/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Islet α cells and glucagon--critical regulators of energy homeostasis.
Autorzy :: Campbell JE; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, 600 University Avenue, TCP5-1004, Toronto, ON M5G 1X5, Canada.
Drucker DJ; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, 600 University Avenue, TCP5-1004, Toronto, ON M5G 1X5, Canada.; Pokaż więcej
Źródło :: Nature reviews. Endocrinology [Nat Rev Endocrinol] 2015 Jun; Vol. 11 (6), pp. 329-38. Date of Electronic Publication: 2015 Apr 07.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Homeostasis*
Blood Glucose/*metabolism
Diabetes Mellitus, Type 1/*metabolism
Diabetes Mellitus, Type 2/*metabolism
Energy Metabolism/*physiology
Glucagon/*metabolism
Glucagon-Secreting Cells/*metabolism
Adipose Tissue/metabolism ; Brain/metabolism ; Diabetes Mellitus, Type 1/drug therapy ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon/physiology ; Glucagon/therapeutic use ; Glucagon-Secreting Cells/physiology ; Hormones/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Liver/metabolism ; Myocardium/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Autorzy :: Finan B; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany. [3] Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
Yang B; 1] Department of Chemistry, Indiana University, Bloomington, Indiana, USA. [2] Marcadia Biotech, Carmel, Indiana, USA.
Ottaway N; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Smiley DL; Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
Ma T; 1] Department of Chemistry, Indiana University, Bloomington, Indiana, USA. [2] Research Center, Beijing Hanmi Pharm., Beijing, China.
Clemmensen C; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
Chabenne J; 1] Department of Chemistry, Indiana University, Bloomington, Indiana, USA. [2] AIT Laboratories, Indianapolis, Indiana, USA.
Zhang L; Marcadia Biotech, Carmel, Indiana, USA.
Habegger KM; Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Fischer K; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
Campbell JE; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Sandoval D; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Seeley RJ; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Bleicher K; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Uhles S; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Riboulet W; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Funk J; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Hertel C; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Belli S; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Sebokova E; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Conde-Knape K; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Konkar A; Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Drucker DJ; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Gelfanov V; Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
Pfluger PT; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
Müller TD; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.
Perez-Tilve D; Metabolic Diseases Institute, Division of Endocrinology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
DiMarchi RD; Department of Chemistry, Indiana University, Bloomington, Indiana, USA.
Tschöp MH; 1] Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. [2] Department of Medicine, Division of Metabolic Diseases,Technische Universität München, Munich, Germany.; Pokaż więcej
Źródło :: Nature medicine [Nat Med] 2015 Jan; Vol. 21 (1), pp. 27-36. Date of Electronic Publication: 2014 Dec 08.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Diabetes Complications/*metabolism
Diabetes Mellitus, Type 2/*metabolism
Obesity/*metabolism
Peptides/*administration & dosage
Animals ; Blood Glucose/drug effects ; Body Weight/genetics ; Diabetes Complications/drug therapy ; Diabetes Complications/genetics ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/genetics ; Glucagon-Like Peptide 1/agonists ; Glucagon-Like Peptide 1/metabolism ; HEK293 Cells ; Humans ; Insulin/biosynthesis ; Insulin/metabolism ; Mice ; Obesity/drug therapy ; Obesity/genetics ; Peptides/chemical synthesis ; Peptides/metabolism ; Rats ; Receptors, Gastrointestinal Hormone/agonists ; Receptors, Gastrointestinal Hormone/metabolism ; Receptors, Glucagon/agonists ; Receptors, Glucagon/metabolism ; Rodentia
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 11 11.

Tytuł :: Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Autorzy :: Lovshin JA; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Barnie A; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.
DeAlmeida A; Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Logan A; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Zinman B; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada.
Drucker DJ; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada drucker@lunenfeld.ca.; Pokaż więcej
Źródło :: Diabetes care [Diabetes Care] 2015 Jan; Vol. 38 (1), pp. 132-9. Date of Electronic Publication: 2014 Nov 20.
Typ publikacji :: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Atrial Natriuretic Factor/*blood
Diabetes Mellitus, Type 2/*drug therapy
Glucagon-Like Peptide 1/*analogs & derivatives
Hypertension/*drug therapy
Natriuresis/*drug effects
Adult ; Aged ; Blood Pressure/drug effects ; Body Weight ; Cross-Over Studies ; Double-Blind Method ; Endpoint Determination ; Female ; Glucagon-Like Peptide 1/administration & dosage ; Glucagon-Like Peptide-1 Receptor ; Heart Rate/drug effects ; Humans ; Liraglutide ; Male ; Middle Aged ; Natriuretic Peptide, Brain/blood ; Obesity ; Peptide Fragments/blood ; Receptors, Glucagon/agonists ; Receptors, Glucagon/blood ; Sodium/urine
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Autorzy :: Mulvihill EE; Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada.
Drucker DJ; Pokaż więcej
Źródło :: Endocrine reviews [Endocr Rev] 2014 Dec; Vol. 35 (6), pp. 992-1019. Date of Electronic Publication: 2014 Sep 12.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl Peptidase 4/*metabolism
Dipeptidyl-Peptidase IV Inhibitors/*pharmacology
Animals ; Clinical Trials as Topic ; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Disease Models, Animal ; Humans ; Mice ; Signal Transduction/drug effects ; Signal Transduction/physiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Cardiovascular actions of incretin-based therapies.
Autorzy :: Ussher JR; From the Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Ontario, Canada.
Drucker DJ; From the Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Ontario, Canada. drucker@lunenfeld.ca.; Pokaż więcej
Źródło :: Circulation research [Circ Res] 2014 May 23; Vol. 114 (11), pp. 1788-803.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: Cardiovascular System/*drug effects
Diabetes Mellitus, Type 2/*complications
Diabetic Angiopathies/*drug therapy
Incretins/*pharmacology
Incretins/*therapeutic use
Animals ; Blood Glucose/metabolism ; Cardiovascular System/physiopathology ; Diabetes Mellitus, Type 2/blood ; Diabetic Angiopathies/physiopathology ; Dipeptidyl Peptidase 4/drug effects ; Disease Models, Animal ; Enzyme Inhibitors/pharmacology ; Glucagon-Like Peptide-1 Receptor ; Humans ; Lipid Metabolism/drug effects ; Mice ; Receptors, Glucagon/agonists ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Metabolic disease puts up a fight: are diet and exercise helpful for the heart?
Autorzy :: Lovshin JA; Department of Medicine, Lunenfeld Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Drucker DJ; Pokaż więcej
Źródło :: Nature medicine [Nat Med] 2013 Oct; Vol. 19 (10), pp. 1216-7.
Typ publikacji :: Journal Article
MeSH Terms :: Diet*
Exercise*
Diabetes Mellitus, Type 2/*physiopathology
Heart/*physiopathology
Diabetes Mellitus, Type 2/diet therapy ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents/therapeutic use ; Weight Loss
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 15 15.

Tytuł :: Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.
Autorzy :: Sadry SA; Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue TCP5-1004, Toronto M5G 1X5, ON, Canada.
Drucker DJ; Pokaż więcej
Źródło :: Nature reviews. Endocrinology [Nat Rev Endocrinol] 2013 Jul; Vol. 9 (7), pp. 425-33. Date of Electronic Publication: 2013 Mar 12.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Diabetes Mellitus, Type 2/*drug therapy
Obesity/*drug therapy
Animals ; Blood Glucose/drug effects ; Body Weight/drug effects ; Central Nervous System/drug effects ; Gastric Inhibitory Polypeptide/therapeutic use ; Glucagon/therapeutic use ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Leptin/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice.
Autorzy :: Rieg T; Dept. of Medicine and Pharmacology, Division of Nephrology/Hypertension, Univ. of California San Diego and VA San Diego Healthcare System, 3350 La Jolla Village Dr. (9151 San Diego, CA 92161, USA.
Gerasimova M
Murray F
Masuda T
Tang T
Rose M
Drucker DJ
Vallon V; Pokaż więcej
Źródło :: American journal of physiology. Renal physiology [Am J Physiol Renal Physiol] 2012 Oct; Vol. 303 (7), pp. F963-71. Date of Electronic Publication: 2012 Jul 25.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Diabetes Mellitus, Type 2/*metabolism
Natriuretic Agents/*pharmacology
Obesity/*metabolism
Peptides/*pharmacology
Piperidines/*pharmacology
Receptors, Glucagon/*metabolism
Uracil/*analogs & derivatives
Venoms/*pharmacology
Animals ; Blood Glucose/metabolism ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Exenatide ; Glucagon-Like Peptide 1/metabolism ; Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents/pharmacology ; Kidney/drug effects ; Kidney/metabolism ; Mice ; Mice, Knockout ; Natriuresis/drug effects ; Phosphorylation/drug effects ; Receptors, Glucagon/genetics ; Uracil/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.
Autorzy :: Drucker DJ; Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, 600 University Ave TCP5-1004, Toronto, ON M5G 1X5, Canada. drucker@lunenfeld.ca
Rosen CF; Pokaż więcej
Źródło :: Diabetologia [Diabetologia] 2011 Nov; Vol. 54 (11), pp. 2741-4. Date of Electronic Publication: 2011 Sep 03.
Typ publikacji :: Journal Article; Comment
MeSH Terms :: Diabetes Mellitus, Type 2/*complications
Diabetes Mellitus, Type 2/*drug therapy
Glucagon-Like Peptide 1/*metabolism
Natural Killer T-Cells/*metabolism
Psoriasis/*complications
Psoriasis/*drug therapy
Receptors, Glucagon/*metabolism
Female ; Glucagon-Like Peptide-1 Receptor ; Humans ; Male
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Incretin-based therapy and the quest for sustained improvements in β-cell health.
Autorzy :: Drucker DJ; Pokaż więcej
Źródło :: Diabetes care [Diabetes Care] 2011 Sep; Vol. 34 (9), pp. 2133-5.
Typ publikacji :: Editorial; Comment
MeSH Terms :: Diabetes Mellitus, Type 2/*drug therapy
Hypoglycemic Agents/*therapeutic use
Insulin-Secreting Cells/*drug effects
Metformin/*therapeutic use
Peptides/*therapeutic use
Venoms/*therapeutic use
Exenatide ; Female ; Humans ; Male
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: The safety of incretin-based therapies--review of the scientific evidence.
Autorzy :: Drucker DJ; Department of Medicine, Samuel Lunenfeld Research Institute, Mt Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. d.drucker@utoronto.ca
Sherman SI
Bergenstal RM
Buse JB; Pokaż więcej
Źródło :: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2011 Jul; Vol. 96 (7), pp. 2027-31.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/*adverse effects
Glucagon-Like Peptide 1/*adverse effects
Hypoglycemic Agents/*adverse effects
Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Hypoglycemic Agents/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Liraglutide.
Autorzy :: Drucker DJ; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada. d.drucker@utoronto.ca
Dritselis A
Kirkpatrick P; Pokaż więcej
Źródło :: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2010 Apr; Vol. 9 (4), pp. 267-8.
Typ publikacji :: Journal Article
MeSH Terms :: Diabetes Mellitus, Type 2/*drug therapy
Glucagon-Like Peptide 1/*analogs & derivatives
Hypoglycemic Agents/*therapeutic use
Adult ; Drug Approval ; Glucagon-Like Peptide 1/pharmacology ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Hypoglycemic Agents/pharmacology ; Liraglutide ; Randomized Controlled Trials as Topic ; United States ; United States Food and Drug Administration
: Czasopismo naukowe

Szczegóły Pełny tekst

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Drucker DJ"" wg kryterium: Autor

Aktywne filtry:

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język